J K Litton1, S A Hurvitz2, L A Mina3, H S Rugo4, K-H Lee5, A Gonçalves6, S Diab7, N Woodward8, A Goodwin9, R Yerushalmi10, H Roché11, Y-H Im12, W Eiermann13, R G W Quek14, T Usari15, S Lanzalone15, A Czibere16, J L Blum17, M Martin18, J Ettl19. 1. The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: jlitton@mdanderson.org. 2. University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, USA. 3. Banner M.D. Anderson Cancer Center, Gilbert, USA. 4. University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA. 5. Seoul National University Hospital, Seoul, South Korea. 6. Institut Paoli-Calmettes, Marseille, France. 7. Rocky Mountain Cancer Centers, Littleton, USA. 8. Mater Misericordiae Ltd/Mater Research Institute and the University of Queensland, Brisbane, Australia. 9. Medical Oncology Department, Concord Repatriation General Hospital, Concord, Australia. 10. Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel. 11. Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France. 12. Samsung Medical Center, Seoul, South Korea. 13. Interdisziplinäres Onkologisches Zentrum München, Munich, Germany. 14. Pfizer Inc., San Francisco, USA. 15. Pfizer Oncology, Milan, Italy. 16. Pfizer Inc., Cambridge, USA. 17. Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas, USA. 18. Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense, Madrid, Spain. 19. Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
Abstract
BACKGROUND: In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P < 0.0001) and improved patient-reported outcomes (PRO) in germline BRCA1/2 (gBRCA1/2)-mutated advanced breast cancer (ABC). We report final overall survival (OS). PATIENTS AND METHODS: This randomized phase III trial enrolled patients with gBRCA1/2-mutated HER2-negative ABC. Patients received talazoparib or physician's choice of chemotherapy. OS was analyzed using stratified HR and log-rank test and prespecified rank-preserving structural failure time model to account for subsequent treatments. RESULTS: A total of 431 patients were entered in a randomized study (287 talazoparib/144 chemotherapy) with 412 patients treated (286 talazoparib/126 chemotherapy). By 30 September 2019, 216 deaths (75.3%) occurred for talazoparib and 108 (75.0%) chemotherapy; median follow-up was 44.9 and 36.8 months, respectively. HR for OS with talazoparib versus chemotherapy was 0.848 (95% CI 0.670-1.073; P = 0.17); median (95% CI) 19.3 months (16.6-22.5 months) versus 19.5 months (17.4-22.4 months). Kaplan-Meier survival percentages (95% CI) for talazoparib versus chemotherapy: month 12, 71% (66% to 76%)/74% (66% to 81%); month 24, 42% (36% to 47%)/38% (30% to 47%); month 36, 27% (22% to 33%)/21% (14% to 29%). Most patients received subsequent treatments: for talazoparib and chemotherapy, 46.3%/41.7% received platinum and 4.5%/32.6% received a poly(ADP-ribose) polymerase (PARP) inhibitor, respectively. Adjusting for subsequent PARP and/or platinum use, HR for OS was 0.756 (95% bootstrap CI 0.503-1.029). Grade 3-4 adverse events occurred in 69.6% (talazoparib) and 64.3% (chemotherapy) patients, consistent with previous reports. Extended follow-up showed significant overall improvement and delay in time to definitive clinically meaningful deterioration in global health status/quality of life and breast symptoms favoring talazoparib versus chemotherapy (P < 0.01 for all), consistent with initial analyses. CONCLUSIONS: In gBRCA1/2-mutated HER2-negative ABC, talazoparib did not significantly improve OS over chemotherapy; subsequent treatments may have impacted analysis. Safety was consistent with previous observations. PRO continued to favor talazoparib.
BACKGROUND: In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P < 0.0001) and improved patient-reported outcomes (PRO) in germline BRCA1/2 (gBRCA1/2)-mutated advanced breast cancer (ABC). We report final overall survival (OS). PATIENTS AND METHODS: This randomized phase III trial enrolled patients with gBRCA1/2-mutated HER2-negative ABC. Patients received talazoparib or physician's choice of chemotherapy. OS was analyzed using stratified HR and log-rank test and prespecified rank-preserving structural failure time model to account for subsequent treatments. RESULTS: A total of 431 patients were entered in a randomized study (287 talazoparib/144 chemotherapy) with 412 patients treated (286 talazoparib/126 chemotherapy). By 30 September 2019, 216 deaths (75.3%) occurred for talazoparib and 108 (75.0%) chemotherapy; median follow-up was 44.9 and 36.8 months, respectively. HR for OS with talazoparib versus chemotherapy was 0.848 (95% CI 0.670-1.073; P = 0.17); median (95% CI) 19.3 months (16.6-22.5 months) versus 19.5 months (17.4-22.4 months). Kaplan-Meier survival percentages (95% CI) for talazoparib versus chemotherapy: month 12, 71% (66% to 76%)/74% (66% to 81%); month 24, 42% (36% to 47%)/38% (30% to 47%); month 36, 27% (22% to 33%)/21% (14% to 29%). Most patients received subsequent treatments: for talazoparib and chemotherapy, 46.3%/41.7% received platinum and 4.5%/32.6% received a poly(ADP-ribose) polymerase (PARP) inhibitor, respectively. Adjusting for subsequent PARP and/or platinum use, HR for OS was 0.756 (95% bootstrap CI 0.503-1.029). Grade 3-4 adverse events occurred in 69.6% (talazoparib) and 64.3% (chemotherapy) patients, consistent with previous reports. Extended follow-up showed significant overall improvement and delay in time to definitive clinically meaningful deterioration in global health status/quality of life and breast symptoms favoring talazoparib versus chemotherapy (P < 0.01 for all), consistent with initial analyses. CONCLUSIONS: In gBRCA1/2-mutated HER2-negative ABC, talazoparib did not significantly improve OS over chemotherapy; subsequent treatments may have impacted analysis. Safety was consistent with previous observations. PRO continued to favor talazoparib.
Authors: Michael P Lux; Thomas Decker; Eva Diana Runkel; Alexander Niyazov; Ruben G W Quek; Norbert Marschner; Nadia Harbeck Journal: Breast Care (Basel) Date: 2021-02-18 Impact factor: 2.860
Authors: Diana Lüftner; Peter A Fasching; Renate Haidinger; Nadia Harbeck; Christian Jackisch; Volkmar Müller; Eva Schumacher-Wulf; Christoph Thomssen; Michael Untch; Rachel Würstlein Journal: Breast Care (Basel) Date: 2022-01-20 Impact factor: 2.860
Authors: M Mego; D Svetlovska; M Reckova; K Kalavska; J Obertova; P Palacka; K Rejlekova; Z Sycova-Mila; M Chovanec; J Mardiak Journal: Invest New Drugs Date: 2021-05-29 Impact factor: 3.850
Authors: Harold J Burstein; Mark R Somerfield; Debra L Barton; Ali Dorris; Lesley J Fallowfield; Dharamvir Jain; Stephen R D Johnston; Larissa A Korde; Jennifer K Litton; Erin R Macrae; Lindsay L Peterson; Praveen Vikas; Rachel L Yung; Hope S Rugo Journal: J Clin Oncol Date: 2021-07-29 Impact factor: 44.544